Aclaris Therapeutics, Inc. Shareholders' Equity
Aclaris Therapeutics, Inc. (ACRS) had Shareholders' Equity of $124.58 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $124.58M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $143.65M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $103.08M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $120.10M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $124.58M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $143.65M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $103.08M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $120.10M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $131.74M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $144.07M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $155.55M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $130.15M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $133.82M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $142.01M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $157.18M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $156.33M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $179.75M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $176.81M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $197.62M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $219.84M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $235.75M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $180.20M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $197.34M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $216.58M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $233.81M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $112.29M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $37.65M 10-K · filed 2024-02-27 | |
| 2020-09-30 | $40.76M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $49.37M 10-Q · filed 2021-11-02 | |
| 2020-03-31 | $58.15M 10-Q · filed 2021-11-02 | $58.17M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $69.91M 10-K · filed 2023-02-23 | |
| 2019-09-30 | $85.28M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $137.23M 10-Q · filed 2020-11-04 | |
| 2019-03-31 | $182.25M 10-Q · filed 2020-11-04 | |
| 2018-12-31 | $215.12M 10-K · filed 2022-02-24 | |
| 2018-09-30 | $146.33M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $174.20M 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $200.47M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $225.26M 10-K · filed 2021-02-25 | |
| 2017-09-30 | $244.26M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $168.14M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $160.29M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $169.49M 10-K · filed 2020-02-25 | |
| 2016-09-30 | $81.12M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $90.24M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $83.21M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $92.52M 10-K · filed 2019-03-18 | |
| 2015-09-30 | -$38.12M 10-Q · filed 2015-12-03 | |
| 2014-12-31 | -$20.75M 10-K · filed 2018-03-12 | |
| 2013-12-31 | -$9.16M 10-K · filed 2017-03-15 | |
| 2012-12-31 | -$2.19M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |